From the FDA: Gardasil Approved for Use in Males
The quadrivalent human papillomavirus vaccine (Gardasil) has been approved to help prevent genital warts in males aged 9 through 26, the FDA announced on Friday. As in girls and young women, the vaccine will be given as three injections over a 6-month period. This is good news since males are carriers of the HPV virus and can infect their female sexual partners.
From the FDA: New HPV Vaccine Approved for Females
The agency also approved a bivalent HPV vaccine (Cervarix), manufactured by Glaxo Smith Kline, for use in females aged 10 through 25, according to the manufacturer. The vaccine, which protects against HPV types 16 and 18, both causes of almost all cervical cancers, is expected to be available in the U.S. by the end of 2009.
FDA news release on Gardasil (Free)
Manufacturer news release on Cervarix [New drug from Glaxo Smith Kline] (Free)